Optometry students are now eligible to certify to prescribe the Brilliant Futures™ Myopia Management Program, and have the opportunity for hands-on experience fitting MiSight® 1 day contact lenses through CooperVision’s Adopt-a-Patient program
SAN RAMON, Calif., April 13, 2021—Committed to furthering myopia management education in the optometric industry, CooperVision is bringing new opportunities to optometry students. Certification for its Brilliant Futures™ Myopia Management Program featuring MiSight® 1 day* contact lenses is now available to third and fourth year students at the 23 schools and colleges of optometry throughout the nation. CooperVision has also added MiSight® 1 day* to its list of products available through the existing Adopt-a-Patient® program.
CooperVision’s MiSight® 1 day contact lens is the first and only soft contact lens the U.S. Food and Drug Administration has approved1* for slowing the progression of myopia in children, aged 8-12 at the initiation of treatment.1†
“As childhood myopia continues to rise in prevalence and severity2, it’s important for all future optometrists to learn how to effectively manage myopia,” said Justin Kwan, OD, Senior Manager of Myopia Management, Professional & Academic Affairs at CooperVision. “Our latest commitment provides students with opportunities to grow their knowledge and have direct experience with the most advanced contact lens technologies, better preparing them for myopia management in practice. Students who proceed with Brilliant Futures™ certification will also stand out amongst their peers as they compete for scholarships, residencies and jobs after graduation.”
Encouraging Student Certification
CooperVision worked with contact lens chiefs at each school and college of optometry to invite all third and fourth year students to attend a student certification launch kickoff, scheduled for April 6 and April 7, 2021. During the event, CooperVision executives, contact lens educator Dr. Anita Gulmiri, and certified ECP Ashley Wallace-Tucker provided insights into how CooperVision is a leader in the myopia management category, why myopia management is important, and the value certification brings as students begin their careers.
Students will receive the same Brilliant Futures™ certification training as practicing eye care professionals, including access to a five course syllabus and optional engagement opportunities with peers and our top certified prescribers via Ask the Expert webinars. Students who successfully complete the curriculum and online exam will earn certification that will follow them as they start their career. Once the student accepts a position, they just need to update CooperVision who will then deploy their myopia team to successfully launch Brilliant Futures™ in their practice.
Encouraging Hands-On Fitting Experience with MiSight® 1 day
Students have the opportunity for a hands-on fitting experience now that MiSight® 1 day is available as part of CooperVision’s Adopt-a-Patient® program. CooperVision has committed to allocating up to 12 MiSight® 1 day annual supplies to each participating school and college of optometry.
Adopt-A-Patient® is intended to be a positive contact lens fitting experience for optometry students during their clinical contact lens internship while serving under-privileged patients. Students are encouraged to “adopt” a deserving patient from their community into the program, fit them with CooperVision soft contact lenses, and provide appropriate follow-up care during their clinical contact lens internship. With MiSight® 1 day added as an available product to the Adopt-a-Patient® program, age-appropriate* patients who may not have the opportunity to wear the contact lenses because of their family’s income level will now benefit greatly.
ECPs and optometry faculty, residents and students who are interested in learning more about the Brilliant Futures™ Myopia Management Program featuring MiSight® 1 day contact lenses can visit www.coopervision.com/practitioner/myopia-management.
# # #
* Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1 day lens over a 3 year period.
1 Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567. Compared to a single vision 1 day lens over a 3 year period.
2 Holden et al, - Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Jamie Palmeroni-Lavis McDougall Communications
firstname.lastname@example.org or +1-585-478-4338